Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.55 |
| ▸ | HTR2C | P28335 | 1/20 | 0.55 |
| ▸ | HTR7 | P34969 | 5/20 | 0.53 |
| ▸ | EGFR | P00533 | 2/20 | 0.45 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.43 |
| ▸ | KRAS | P01116 | 4/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14061899 | 0.95 | HTR2A (0.59) | HTR2AHTR2CHTR7EGFRNTSR1 | |
| SCHEMBL4939152 | 0.85 | HTR2A (0.56) | HTR2AHTR2CHTR7EGFRNTSR1 | |
| SCHEMBL18856950 | 0.84 | HTR2A (0.55) | HTR2AHTR2CHTR7EGFRNTSR1 | |
| SCHEMBL14790349 | 0.83 | SCN9A (0.47) | HTR2AHTR2CHTR7EGFRNTSR1 | |
| SCHEMBL15550237 | 0.83 | HTR2A (0.54) | HTR2AHTR2CHTR7EGFRNTSR1 | |
| SCHEMBL28550149 | 0.83 | HTR2A (0.54) | HTR2AHTR2CHTR7EGFRNTSR1 | |
| SCHEMBL22930065 | 0.83 | HTR2A (0.54) | HTR2AHTR2CHTR7EGFRNTSR1 | |
| SCHEMBL18239699 | 0.81 | HTR7 (0.57) | HTR2AHTR2CHTR7 | |
| SCHEMBL3478164 | 0.81 | HTR2A (0.63) | HTR2AHTR2CHTR7NTSR1SLC6A2 | |
| SCHEMBL21941497 | 0.78 | HTR2A (0.59) | HTR2AHTR2CHTR7NTSR1KRAS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170166555-A1 | FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS | NOVOGEN LIMITED (AU) | 2017-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166555-A1 | FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS | TPM3, TPM4, TNNI3 | HTR2A 1880/4885HTR2C 1642/4885HTR7 1063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.